Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0024523 (
malabsorption
)
7,319
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The effect of molecular weight, lymph quality (total lipid content) and pathological conditions (liver cirrhosis,
malabsorption
state, acute uremia) on the distribution of model drugs into central lymph after i.v. administration was studied in rats. Lymphatic bioavailability (FL), expressing the ratio of the areas under both the lymphatic and the blood concentration curves, served as the parameter of "lymphotropy". In model drugs with a low molecular weight (benzoates, hippurate, diazepam), the blood and lymphatic concentrations are steady (FL values are close to 1.00). Inulin (m.w. = 5600) in small doses (0.75 mg/kg) possesses a FL similar to low-molecular substances; additions of 10-fold and 50-fold doses significantly increase the FL. High--molecular
HSA
passes into the lymph to a limited degree only (FL = 0.49). The content of lipids in the central lymph determines the magnitude of FL for the lipophilic drug (diazepam) only. The induced pathological conditions affect the absolute values of both the blood lymphatic areas under the concentration curves, but the resultant FL varies only slightly.
...
PMID:On the limiting factors affecting the distribution of model drugs from blood into the lymphatic system. 182 Sep 25